3/22
10:09 am
nuvl
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth [Yahoo! Finance]
Low
Report
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth [Yahoo! Finance]
3/6
11:58 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $98.00. They now have an "overweight" rating on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $98.00. They now have an "overweight" rating on the stock.
3/5
05:00 pm
nuvl
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 [Yahoo! Finance]
Medium
Report
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 [Yahoo! Finance]
3/5
04:52 pm
nuvl
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
Medium
Report
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
2/29
04:49 am
nuvl
Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... [Yahoo! Finance]
Low
Report
Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... [Yahoo! Finance]
2/28
10:16 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at BMO Capital Markets from $93.00 to $102.00. They now have an "outperform" rating on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at BMO Capital Markets from $93.00 to $102.00. They now have an "outperform" rating on the stock.
2/28
08:05 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Guggenheim. They set a "buy" rating and a $99.00 price target on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Guggenheim. They set a "buy" rating and a $99.00 price target on the stock.
2/28
05:30 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "market perform" rating re-affirmed by analysts at Leerink Partnrs.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "market perform" rating re-affirmed by analysts at Leerink Partnrs.
2/27
05:36 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $99.00 price target on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $99.00 price target on the stock.
2/27
07:38 am
nuvl
Nuvalent lung cancer candidate gets FDA breakthrough therapy status [Seeking Alpha]
Low
Report
Nuvalent lung cancer candidate gets FDA breakthrough therapy status [Seeking Alpha]
2/27
06:33 am
nuvl
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/27
06:30 am
nuvl
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
2/27
06:20 am
nuvl
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 [Yahoo! Finance]
Low
Report
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 [Yahoo! Finance]
2/27
06:15 am
nuvl
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Low
Report
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
2/23
06:38 pm
nuvl
Baird starts Nuvalent at outperform, cites potential of lead assets [Seeking Alpha]
Low
Report
Baird starts Nuvalent at outperform, cites potential of lead assets [Seeking Alpha]
2/23
07:31 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $105.00 price target on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $105.00 price target on the stock.
2/12
06:18 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $99.00 price target on the stock, up previously from $82.00.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $99.00 price target on the stock, up previously from $82.00.
2/12
06:33 am
nuvl
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors [Yahoo! Finance]
Low
Report
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors [Yahoo! Finance]
2/12
06:30 am
nuvl
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
Low
Report
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
2/1
06:30 am
nuvl
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Medium
Report
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
1/8
12:25 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $82.00 price target on the stock, up previously from $74.00.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $82.00 price target on the stock, up previously from $74.00.
1/8
06:39 am
nuvl
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones [Yahoo! Finance]
Low
Report
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones [Yahoo! Finance]
1/8
06:30 am
nuvl
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
Low
Report
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
1/1
08:39 am
nuvl
Nuvalent, Inc. (NASDAQ:NUVL) Shares Could Be 35% Below Their Intrinsic Value Estimate [Yahoo! Finance]
Low
Report
Nuvalent, Inc. (NASDAQ:NUVL) Shares Could Be 35% Below Their Intrinsic Value Estimate [Yahoo! Finance]